You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Tumor and stromal cell biology
733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202084011
Dec 20201003
Jan 20211202
Feb 20211202
Mar 20213605
Apr 20212405
May 2021504
Jun 2021005
Jul 2021004
Aug 2021006
Sep 2021005
Oct 202122021
Nov 20218011
Dec 20211201
Jan 20222203
Feb 20222401
Mar 20224806
Apr 20223403
May 20221801
Jun 20221600
Jul 20221200
Aug 20222602
Sep 20222001
Oct 20221201
Nov 20221200
Dec 20222000
Jan 20232600
Feb 20231800
Mar 20232002
Apr 2023604
May 20232402
Jun 20233803
Jul 2023803
Aug 20232005
Sep 20231000
Oct 20231602
Nov 20231202
Dec 20234400
Jan 20241800
Feb 20242400
Mar 20241000
Apr 20241000
May 20242000
Jun 20242000
Jul 20243204
Aug 20242404
Sep 20242803
Oct 20241407
Nov 20243400
Dec 20244003
Jan 20251605
Feb 2025201
Mar 2025001
Apr 2025002
May 2025002
Jun 2025004
Total10230162